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The T cell specific adapter protein (TSAd) is expressed in activated T cells and NK cells. While TSAd is
beginning to emerge as a critical regulator of Lck and Itk activity in T cells, its role in NK cells has not yet
been explored. Here we have examined susceptibility to virus infections in a murine model using various
viral infection models. We report that TSAd-deficient mice display reduced clearance of murine
cytomegalovirus (MCMV) that lack the viral MHC class I homologue m157, which is critical for
Ly49H-mediated NK cell recognition of infected cells. In this infection model, NK cells contribute in the
early stages of the disease, whereas CD81T cells are critical for viral clearance.We found that mice infected
withMCMVDm157 displayed reduced viral clearance in the spleen as well as reduced proliferation in spleen
NK cells and CD81T cells in the absence of TSAd. Though no other immunophenotype was detected in the
infection models tested, these data suggests that in the absence of the Ly49H ligand activation, NK cell and
CD81 T cell responses may be compromised in TSAd-deficient mice.
T
he recognition of antigens by the T cell receptor (TCR) is crucial in order to mediate T cell dependent
responses. Triggering of the TCR leads to downstream signal propagation through a sequence of phosphor-
ylation events modulated by various adaptor proteins. One of these adaptors, encoded by the Sh2d2a gene, is
T cell specific adapter protein (TSAd), which is upregulated in activated T cells1.
T cells from Sh2d2a 2/2mice display impaired production of IFNc upon TCR stimulation in vitro2 and in vivo3.
Early characterization of Sh2d2a 2/2mice indicated that TSAd regulated autoimmunity, as T cells from Sh2d2a 2/2
mice were more resistant to antigen-induced cell death in vivo and older Sh2d2a 2/2 mice developed lupus-like
symptoms3. Recently, improved T cell mediated protection against a transplanted myeloma in Sh2d2a2/2 mice
has been observed indicating that TSAd has a modulatory role in T cell mediated immune surveillance of cancer4.
Though the characterisation of TSAd’s function in vivo remains incomplete, these studies of TSAd suggest that
the adaptor may be an important regulator of normal T cell function.
Biochemical characterization of TSAd’s role in T cell activation has revealed that TSAd modulates the activity
of Lck throughmulti-site docking of Lck to TSAd5. TSAd interacts with Itk, and primes Itk for phosphorylation by
Lck6. It is thus likely that TSAd modulates signalling in activated T cells via interaction with Lck and Itk5–8.
Although TSAd is also highly expressed in NK cells9, the role of TSAd in NK cell function has not been
explored. TSAd expression is induced upon activation of both T and NK cells andmany of the known interaction
partners for TSAd such as Lck, Itk, Src andMEKK22,10–13 are also expressed in NK cells. Importantly, Lck and Itk
are expressed almost solely in T andNK cells and are important for efficient NK cell cytotoxicity and survival12–16.
There is compelling evidence for the role of NK cells against virus infections such as coxsackievirus B317,
influenza virus18 as well as a potential role in herpes simplex virus 1 (HSV1) infection19. The best characterized
model however remains the functional impact of NK cells against mouse cytomegalovirus (MCMV). In C57BL/6
mice, NK cells expressing the activating receptor Ly49H are responsible for the control of MCMV replication20,21.
Ly49H binds to the viral glycoprotein m157 which is expressed at the surface of infected cells within hours of
infection22. This binding triggers signaling pathways that activate NK cell effector functions such as IFNc secretion,
release of cytotoxic granules containing perforin and granzymeB, as wells as proliferation of Ly49H1 NK cell
subsets22. The antiviral response toMCMV also involves CD41 T cells, NK-T cells as well as neutrophils. CD41 T
cells are critical for controling virus load in the salivary glands, but not the spleen, lung or liver23,24. A recent report
demonstrated that depletion of neutrophils increases virus load in several organs including liver, salivary gland and
lungs but not in the spleen25. NK-T cells are activated by MCMV and have been shown to synergize with NK cells
for the clearance of MCMV in a BALB/c model, although this occurs principally in the liver26.
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Finally, an MCMV strain that lacks the m157 protein (Dm157
MCMV) and thus bypasses the stringent Ly49H NK cell response27
has enabled the discovery of CD81 T cell and NK cell cross talk
during viral infection28. While CD81 T cells have only a minor role
in the control of wild typeMCMV, they have a critical function in the
clearance of m157-deficient virus28. This detailed understanding of
MCMV and its interaction with NK and CD81 T cells together with
availability of Sh2d2a 2/2 mice provide ideal tools for investigating
the function of TSAd in the context of infection.
Here, we report the use of various virus infection models, includ-
ing Dm157MCMV, to assess the function of TSAd during a primary
viral infection. Absence of an altered anti-virus response in wild type
MCMV infected Sh2d2a 2/2 mice, and impaired viral clearance in
Dm157 MCMV infected Sh2d2a 2/2 mice indicates that TSAd does
not modulate NK cell function through the Ly49H activating path-
way and suggests that TSAd is implicated in T cell mediated elim-
ination of virus infected cells.
Results and discussion
TSAd is expressed in NK cells. To confirm expression of TSAd in
activated NK cells from C57BL/6 Sh2d2a 1/1 mice, splenic NK cells
were cultured in the presence IL-2 for six to eight days. Western blot
analysis demonstrated expression of TSAd in IL-2 activatedNK cells,
and increased expression following incubation in a cocktail of PMA
plus ionomycin. Similarly, the human NK cell line NKL (cultured in
IL-2) demonstrated increased expression of TSAd following induc-
tion with PMA/ionomycin as analysed by western blot (Figure 1A–
B). The mouse NK cells displayed a rapid increase in TSAd expres-
sion, evident as early as 10 minutes following PMA/ionomycin
stimulation indicating that the expression of TSAd is regulated
also at the translational level as reported earlier29. In contrast, the
human NKL cell line displayed a slower response, with TSAd
expression peaking eight hours after stimulation (Figure 1A–B).
The amount of TSAd in primary human NK cells from blood as
analysed by flow cytometry was not affected by addition of IL-2,
However, a significant increase in amount of TSAd was observed
upon treatment with IL-2/PHA or PMA/Ionomycin (Figure 1C–D).
TSAd deficient mice display reduced clearance of Dm157 MCMV
infection in the spleen. In order to determine if TSAd influences
host resistance to MCMV infection, Sh2d2a 2/2 mice and their
Sh2d2a 1/1 littermates were infected with both wild type (Smith
strain) MCMV and the Dm157 MCMV strain, lacking the m157
gene, and viral titers in spleen and liver were determined. Infection
with MCMV at day 4 did not show a difference between Sh2d2a2/2
and wild type mice neither in the spleen nor the liver (Figure 2A–B).
In contrast, 5 days post infection with Dm157MCMV, the Sh2d2a 2/2
mice displayed higher viral titers in the spleen but not the liver, than
the Sh2d2a 1/1 mice (Figure 2C–D). NK cells are critical in clearing
MCMV via recognition of the viral MHC homologue m157 by
Ly49H28,30. The observation that wild type MCMV was cleared
equally well in TSAd deficient mice and wild type mice
(Figure 2A–B), indicates that TSAd is not critical for clearance of
the virus by Ly49H-dependent NK cells.
MCMV infection of mice lacking Ly49H (B6. Ly49h-deficient
mice) leads to high splenic viral titer, disorganization of the spleen
architecture and dramatic attrition of lymphocytes during the first
three days after infection30. In absence of Ly49H signaling, however,
CD81 T cells have been shown to be critical for the control of
infection28,30. This was demonstrated in a model whereby C57BL/6
mice are infected with Dm157 MCMV28,30. Already by day 4 post-
infection, CD81 T cells express activation markers and, by day 7,
there is robust proliferation and cytokine secretion of antigen-spe-
cific CD81 T cells28,30.
Figure 1 | TSAd expression in NK cells. (A) Human NK-L cell line was stimulated with 200 U/ml of IL-2 or 100 ng/ml of PMA and 500 ng/ml of
Ionomycin (PMA/I) for the indicated time points. The cells were then lysed and the expression of TSAd was analysed byWestern blot. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) served as loading control for total protein level (Top).Mouse NK cells prepared from total splenocytes and cultured
with recombinant human IL-2 (1000 U/mL) for 6 to 8 days were stimulated with PMA/I for the indicated time-points and TSAd expression was
monitored by Western blot as indicated above (Bottom). (B) Densitometry analysis was performed on the Western blot data, shown as TSAd/GAPDH
ratio. (C andD) PBMC fromhealthy volunteers were stimulated with 200 U/ml of IL-2 or 200 mg/ml of PHA alongwith 200 U/ml of IL-2 or 100 ng/ml of
PMA and 500 ng/ml of Ionomycin for 24 h. (C) TSAd expression in NK cells (CD3-, CD561) from PBMC were analysed by flow cytometry.
(D) Graphical representation of the TSAd expression levels in humanCD3-CD561 cells1/2 SEM (*p, 0.05). Each dot represents an individual donor.
www.nature.com/scientificreports
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TSAd is highly expressed in activated T cells. Thus the reduced
clearance of Dm157MCMV in the spleens of Sh2d2a 2/2mice could
be caused by deficiency in CD81 T cell activation or function.
However, an early NK cell response modulates CD81T cell function
during Dm157MCMV infection28. Deficient NK cell function could
also explain the reduced viral clearance in the spleen. Thus, the
higher Dm157 MCMV titers seen in Sh2d2a 2/2 mice could be due
to defective early NK-CD81 T cell responses or crosstalk. This dys-
function may be masked in wild type MCMV infection by the potent
Ly49H-mediated effect resulting in normal resistance to the virus28.
In order to assess the relative importance of T cells versus NK cells
in the reduced Dm157 MCMV clearance in Sh2d2a2/2 mice, we
assessed the absolute numbers and proportions of cell types in the
spleen before and after MCMV or Dm157 MCMV infection in
Sh2d2a 2/2mice and their wild type littermates (Figure 3). To capture
the contribution of both cell types, mice were examined on day 5
post-infection. A minor but significant decrease in the percentage of
CD81 T cells was observed in both non-infected as well as infected
Sh2d2a 2/2mice compared to their wild type littermates (Figure 3A).
Moreover, no significant changes were observed between Sh2d2a 2/2
and Sh2d2a 1/1mice in absolute T cell numbers (Figure 3B). Thus the
relative decrease in the percentage of CD81 T cells is likely due to an
influx of another cell type, as there is no difference in the total
numbers of CD81 T cells present in the spleens of Sh2d2a 1/1 and
Sh2d2a 2/2mice. Indeed the numbers of CD41T cells and B cells are
both nominally increased in Sh2d2a 2/2 mice compared to controls
although the difference does not reach significance (Fig. 3B). B cells
are required for the initial type I IFN response toMCMV31. However,
as TSAd is not expressed in B-cells, we find it less likely that these
cells are responsible for the reduced clearance of Dm157 MCMV in
Sh2d2a 2/2mice. Finally, NK cell numbers shownomajor differences
between the two groups (Figure 3B), suggesting a possible functional
defect in NK or CD81 T cells.
NK cells from TSAd deficient mice display normal distribution of
maturation and activation markers in vivo and in vitro. NK cell
maturation was analyzed by the expression of CD27 and CD11b
during infection with Dm157 MCMV in spleen lymphocytes. The
order of maturity from least to most mature is CD11blowCD27low,
CD11blowCD27high, CD11bhigh CD27high and finally CD11bhighCD27low32.
As the cell matures along these stages, the NK cell effector functions
change, and the levels of CD11b and CD27 expression may thus
correlate with how capable the population of NK cells are at
clearing MCMV.
In order to assess whether there was a difference in NKmaturation
between Sh2d2a2/2mice and wild type controls, levels of CD11b and
CD27 on the surface of NK cells were analyzed 5 days post infection
with Dm157 MCMV. No differences in any of the stages were
observed between Sh2d2a 2/2 mice and their wild type littermates
(Figure 4A–C). The level of the activationmarker KLRG1onNK cells
Figure 2 | Sh2d2a genotype influences host control of MCMV Dm157 but not MCMV virus replication. Sh2d2a1/1 and Sh2d2a 2/2 littermates were
infected with 7000 PFU of MCMV (Smith strain) or 2 * 106 PFU of MCMV Dm157 virus via the intravenous route. (A–B) At day 4 p.i. mice were
sacrificed and theMCMVviral titers fromA) spleens and B) livers were determined by standard plaque assays using BALB/cmouse embryonic fibroblasts.
(C–D) After MCMV Dm157 infection, viral titers were determined 5 days post-infection in the spleen (C) and liver (D) by standard plaque assays using
BALB/c mouse embryonic fibroblasts. Each dot represents an individual mouse and results are expressed as mean1/2 SEM. (**p, 0.005). One out of
two representative experiments is shown.
www.nature.com/scientificreports
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also showed no difference prior to and after 5 days ofDm157MCMV
infection (Figure 4D). Thus, the maturity and activation profile of
NK cells are similar in the two groups of mice.
To investigate whether lack of TSAd had an effect on the ability of
NK cells to be activated and produce IFNc, total splenocytes were
stimulated in vitro with antibodies against the activating NK cell
receptors Ly49D, Ly49H, NKp46 or NK1.1. Stimulation with IL12
1 IL18 or PMA plus ionomycin served as positive controls. IFNc
expression in NK cells was subsequently measured by flow cytome-
try. No differences in IFNc expression were observed between NK
cells from Sh2d2a2/2 and wild type donors (Figure 4E). Also, the
levels of IFNc in CD81 T cells upon IL121 IL18 or PMA/ionomy-
cin stimulation were not significantly different between Sh2d2a 2/2
and wild type mice (data not shown).
Reduced proliferation of TSAd deficient NK and CD81 T cells
during infection with Dm157 MCMV. Although Sh2d2a 2/2 mice
are capable of clearingMCMV infection, there may be a defect in the
ability of NK cells to proliferate in the absence of TSAd. TSAd’s effect
on the proliferation of T cells has been disputed. Some studies have
found that absence of TSAd reduces T cell proliferation2, while others
have not4,33. In order to investigate TSAd’s role in NK cell prolifera-
tion, BrdU incorporation was measured in splenocytes from Sh2d2a 2/2
mice and their wild type littermates 5 days after Dm157 MCMV
infection. Five days after infection we observed a significant
decrease of 50% on average in the total number of NK cells in
infected mice, as it has been previously reported28,30 (Figure 4F).
The number of NK cells during infection was not significantly
different between Sh2d2a 2/2 mice and controls (Figure 4F). In con-
trast, while the total number of BrdU1 NK cells in spleen remained
similar at day 5 post infection Dm157 MCMV (Figure 4G), a lower
proportion of spleen NK cells were BrdU1 in TSAd deficient mice
(Figure 4H). This suggested reduced NK cell proliferation in the
absence of TSAd in Dm157 MCMV infection. The reduced BrdU
incorporation, in the presence of similar NK cell numbers, indirectly
implicates a higher turnover of NK cells in the wild type animals. No
difference in cell number but a difference in the proportion of
BrdU1 CD81 T lymphocytes was also observed in Sh2d2a 2/2
mice during Dm157 MCMV infection (Figure 4I–K). The decay in
NK cells 5 days post-infection was previously described during
infection with Dm157 MCMV28,30. Here we show that at this early
time-point after infection CD81 T cells display normal levels both in
wild-type and Sh2d2a 2/2mice (Figure 4J), possibly because CD81 T
cells have already recovered. No significant differences were observed
in the numbers or frequency of BrdU uptake in CD41 T cells (data
not shown).
To examine whether the proliferation defect in Sh2d2a 2/2 NK
cells was at the level of receptor repertoire and recognition, the frac-
tions of NK cell populations expressing the activating or inhibitory
NK cell receptors KLRG1, Ly49A, Ly49C, Ly49D, Ly49H and
NKG2A on the surface were measured by flow cytometry. No sig-
nificant differences between Sh2d2a 2/2 mice and their wild type
littermates were observed for these receptors (Figure 4L). The
decreased BrdU1 incorporation in NK cell and CD81 T cells from
Sh2d2a 2/2mice could be the result of an increased cell turnover or an
increased migration towards peripheral target organs of MCMV
infection. NK cells from the spleen migrate via a chemokine-cyto-
kine-chemokine pathway towards the liver. The liver is an important
organ of MCMV replication, and at later time-points during infec-
tion,NK cells andCD81T cells have been shown to contribute to the
control of virus titer in this organ.
Normal susceptibility to herpes simplex virus 1, coxsackievirus B3
and influenza virus infections in TSAd deficient mice. To further
explore the role of TSAd in anti-viral immune responses, three
additional viral infection models were explored: herpes simplex
virus 1, coxsackievirus B3 and influenza virus. Quite different in
their genomes and inducing qualitatively different host responses; all
three viruses have a strong public health impact and their clearance is
mostly mediated by T cells and NK cells. No differences between
Sh2d2a 2/2 mice and their wild type littermates were observed in
the resistance towards these three viruses (Suppl. Figure 1).
Conclusion. There is currently no evidence that TSAd directly
modulates NK cell efficacy in clearing viral infections. Indeed, this
study revealed no difference in resistance toMCMV, herpes simplex,
coxsackie virus or influenza virus of Shd2a2/2 mice. Interestingly,
infection with the Dm157 MCMV variant yielded higher viral titers
in the spleens but not livers of Shd2a2/2mice. Our results also suggest
a reduced proliferative response in spleen NK cells in TSAd deficient
mice. Taken together with the observed normal clearance of wild
type MCMV, our data indicate that TSAd does modulate NK cell
function, but is not necessary for activation of NK cells through the
Ly49H activating receptor.
The reason why Sh2d2a 2/2 mice did not show a defect in viral
clearance in the liver upon Dm157 MCMV infection could be the
tissue specific antiviral role of NK cells. For example NK cells from
salivary glands, an important reservoir of persistent MCMV infec-
Figure 3 | Cell populations of the splenic compartment in Sh2d2a 1/1 and Sh2d2a 2/2 mice. Mice were infected with 8000 PFU of WT MCMV or 2 *
106 PFU of Dm157 MCMV. Splenocytes were harvested from uninfected mice or at day 5 post-infection and analyzed for proportions (A) or absolute
numbers (B) of spleen cell populations1/2 SEM (*p , 0.05; **p , 0.005). Each dot represents an individual mouse One out of two representative
experiments is shown.
www.nature.com/scientificreports
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tion, are hyporesponsive34. Equally, even inMCMV-resistant mice at
relatively early times post-infection, which is those that were chosen
for this study, control of virus replication by NK cells occurs prin-
cipally in the spleen35.
In response to MCMV infection, NK cells secrete cytokines, dis-
play cytotoxic activity and proliferate. In the liverMCMV induces an
innate cytokine/chemokine network involving the recruitment of
MIP-1a producing macrophages. MIP-1a is a chemoattractant also
for INFc producing NK cells, which are able to control virus load in
the liver starting at around day 636,37. It is therefore likely that any
defect in viral clearance in the liver would be observed only after day
5, which was examined in this study.
Important biological functions can often be difficult to reveal in
knock-outmodels because of functional redundancies. Thismay also
be the case of TSAd, thus other signaling proteins and alternate
pathways may have compensated for the lack of TSAd in these
experiments. Although more advanced models could help reveal
the mechanistic role of TSAd in NK cells in virus infections, our data
indicate that TSAd is involved in modulating viral clearance, and
provide a direction for further dissecting the observed susceptibility
in the context of Dm157 MCMV infection.
Methods
Ethical Statement. Human PBMC were collected with informed consent from
healthy blood donors. Collection and analysis of samples were approved by and
performed in accordance with the guidelines of the regional ethical committee. The
animal protocols and experiments were approved by and performed in accordance
with the guidelines of the National Animal Research Authority (Oslo, Norway), the
Canadian Council on Animal Care (CCAC) and the McGill University Animal
Resources Center.
Mice.The Sh2d2a 2/2C57BL/6mice have been previously described2,6. Briefly Sh2d2a
knockout mice were backcrossed on a C57BL/6–129 background (N8, kindly
provided by Professor Jeffrey Bluestone2) to C57BL/6 (purchased from the
Norwegian Institute of Public Health) for more than 10 generations and then to
homozygosity for the disrupted Sh2d2a allele.
In vitro TSAd expression.Mouse NK cell cultures were generated by culturing total
splenocytes in recombinant human IL-2 (1000 U/mL) for 6 to 8 days. The proportion
of NK cells was then verified by flow cytometry with more than 90% purity (CD49b
(DX5)1, CD3-). 2 3 106 cells were left unstimulated, or stimulated for indicated
times with PMA (100 ng/ml) and ionomycin (1 mg/ml) then lysed in presence of
protease inhibitors, and phosphatase inhibitors before being subjected to western
blotting.
Human NKL cells were grown in complete RPMI-1640 media (10% fetal bovine
serum, 1 mM sodium pyruvate, 10 mM HEPES, 1% Pen/strep; Wisent) with the
addition of 200 U/ml of IL-2. 23 106 cells (13 106 cells/ml) human PBMC andNKL
cells were stimulated with 100 ng/ml of PMA and 500 ng/ml of ionomycin for dif-
ferent time intervals depicted in the figure legends. For western blot analysis, cells
were lysed using 0.1% LDS-1% Triton X-100 solution containing 50 mM HEPES,
0.05 M lithium chloride, 0.5 mM PMSF, 2.5 mM EDTA (pH 8.0), 1 mM sodium
vanadate and 1% Triton. The cells were lysed with LDS for 15 min and then with
Triton for 30 min. After lysis, the cells were sonicated, boiled with SDS loading buffer
before proteins were separated by SDS-PAGE and transferred to PVDF membrane
(Bio Rad) using aHoefer Semi-Phor Semi-Dry transfer unit (AmershamBiosciences).
Figure 4 | In vivo and in vitro Immunophenotying of NK cells in Sh2d2a 1/1 and Sh2d2a 2/2mice. Total leukocytes were isolated frommice uninfected
or infected with 2 * 106 PFUofMCMVDm157 for 5 days. Ex vivo spleenNK cell subsets were gated according to surface expression ofmaturationmarkers
CD11b and CD27 (A–C) or expression of KLRG1 (D). Explanted lymphocytes from uninfected Sh2d2a1/1 and Sh2d2a2/2mice served to determine in
vitroNK cell expression levels of IFNa˜ upon stimulation with plate bound antibodies (x-axis), PMA/Ionomycin and IL12/IL18 (E). Total number of CD3-
DX51 splenocytes before and after infection with Dm157 for 5 days (F). NK proliferation was monitored by BrdU incorporation and staining with anti-
BrdU in CD3-DX51 splenocytes ex vivo. Total number (G) and frequency (H) of BrdU positive cells was determined by flow cytometry. Total number of
CD3-CD81 splenocytes before and after infection with Dm157 for 5 days (I). CD81 T cell proliferation was monitored by BrdU incorporation and
staining with anti-BrdU in CD3-DX51 splenocytes ex vivo. Total number (J) and frequency (K) of BrdU positive cells was determined by flow cytometry.
Explanted lymphocytes from uninfected Sh2d2a1/1 and Sh2d2a2/2 mice served to determine in vitro levels of surface activating and inhibitory NK cell
receptors (L). Results are expressed as mean 1/2 SEM. *,0.05, **,0.05.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9219 | DOI: 10.1038/srep09219 5
The membranes were blocked with Tris-buffered saline (pH 7.4) containing 0.1%
Tween 20 (Sigma Aldrich) and 5% skimmed milk, and subsequently incubated with
Anti-TSAd (Origene), Anti-GADPH (Chemicon) or Goat anti Mouse (Jackson) in
blocking buffer containing 1% skimmed milk. Signals were detected using ECF
substrate (GE Healthcare, Pittsburgh, PA, USA) and Storm 860 (GE). Densitometry
analysis was performed on the Western blot data using ImageJ.
MCMV viruses, Infections andViral Loads. Salivary glandMCMVwas prepared by
passaging the virus (Smith strain ATCC VR-1399) twice in 3-week old BALB/c mice.
The virus was prepared from a homogenate of salivary glands 21 days p.i. Mice aged
between 7 and 9 weeks were infected intravenously with 8,000 PFUs of MCMV for 3
or 5 days. The tissue culture-grown viruses38 Dm157 MCMV, which lacks the m157
open reading frame (ORF), have been previously described39. Mice were infected with
2 * 106 PFU of Dm157 MCMV for 5 days. Viral titers of the stock virus or mouse
organs (spleen and liver) were evaluated in vitro by standard plaque assays on a
confluent BALB/c mouse embryonal fibroblast monolayer, as previously described40.
Flow cytometry. For analysis of PBMC cells by flow cytometry after stimulation, the
cells were stained for surface markers (CD3-PE (Immunotools) and CD56-PE-Cy7
(eBioscience)) for human PBMC in PBS containing 2% FCS and 0.1% NaN3 at 4uC.
Cells were then fixed in 2% paraformaldehyde and permeabilized in 0.1% saponin
before intracellular staining with anti-TSAd-Dyelight 488 (3C7) from Origene. For
analysis of splenic leucocytes from mice, spleens from MCMV-infected and
uninfected mice were removed aseptically and gently mashed through a 70 mmnylon
mesh (BD Bioscience). Red blood cells were lysed with Ack’s Lysis Buffer and the
remaining cells were resuspended in the FACS staining buffer. All cells were
incubated with 2.4G2 antibodies to block Fc receptors prior to staining, then stained
with extracellular Ab, fixed, permeabilized and stained for intracellular antigens using
BD cytofix/cytoperm kit according to the manufacturer’s protocol. To detect
incorporated BrdU on NK and T cells, mice were injected i.p. with BrdU (sigma)
3 hours before sacrificing and collecting the spleen. The cells were first blocked with
2.4G2 antibody and stained for surface antigens and then fixed, permeabilized,
treated with DNase I, and stained with FITC-conjugated anti-BrdU antibody (clone
3D4; BD Biosciences), according to the manufacturer’s protocol. All the antibodies
used in this workwere purchased from e-Bioscience, Biolegend or R&D systems, CD3
(2C11), CD4 (GK1.5), CD8 (53–6.7), B220 (RA3-6B2), CD11b (M1/70), CD27
(LG.3A10), DX5 (CD49b), NKp46 (CD335), Ly49A/D (12A8), Ly49C/F/H/I (14B11),
Ly49D (4E5), NKG2A/C/E (20d5), KLRG1 (2F1), Ly49H (3D10), IFNg (XMG1.2).
In vitro Cell Stimulations. Splenocytes were extracted and prepared as described
above. Prior to 2.4G2 blocking and staining, cells were aliquoted into a 96-well 2HB
Immulon plate that had been coated with purified antibody against NK1.1, NKp46,
Ly49H, Ly49D, a cocktail of all mentioned antibodies or PMA/Ionomycin or IL121
IL18 as a positive control. Cells were stimulated in complete RPMI-1640 media with
protein transport inhibitors (GolgiStop or Golgiplug; BD). Cells were then incubated
for 5 h at 37uC, and then extracellular and intracellular staining was performed as
described in the FACS section.
Herpes Simplex Virus 1 Infection and Phenotyping.Details of the HSV-1 infection
procedure have been previously described41. Briefly,mice 7weeks of age or older were,
when indicated, infected intraperitoneally (i.p.) or intranasally (i.n.) with 1.104 or
5.103 PFU of HSV-1 strain 17, respectively. In the i.n. inoculation model, mice were
anesthetized prior to infection with 5 mg/ml ketamine and 15 mg/ml xylazine.
Infected mice were monitored 1–2 times daily over a 2-week period for survival and
weight loss. Mice that succumbed to infection within 14 days post-infection (p.i.)
were considered susceptible to HSV-1.
Coxsackievirus B3 Infection and Phenotyping, weight loss, PA and Myocarditis
Score.Mice were inoculated intraperitoneally with 10 PFU of CVB3 H3 (generously
provided as a plasmid by the laboratory of Dr. Kirk Knowlton42) per gram of body
weight at 7–8 weeks of age. Animals were weighed daily and at day 8 post-infection,
hearts were removed aseptically and sagittally bisected. Heart viral titers were
quantified as previously described43. Heart sections were fixed in 10% formalin and
embedded in paraffin. Samples were sent to the Histology core at the University of
Montreal where sections were prepared. Contiguous heart sections were fixed on
slides and stained with hematoxylin and eosin (H&E) for evaluation of myocarditis as
previously described44.
Influenza Infection and weight loss. Mice were anesthetized with a ketamine/
xylazine mixture and infected via intra-nasal inoculation. Each mouse received a
weight-adjusted dose of 68 PFU/g of themouse adapted influenza strain A/HK/1/68-
MA20. This strain was derived from a H3N2 clinical isolate of seasonal human
influenza from the 1968 Hong Kong pandemic, as previously reported45. The
bodyweight of animals was monitored daily for two weeks following infection. Mice
presenting respiratory distress were humanely sacrificed.
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